| scholarly article | Q13442814 |
| P2093 | author name string | Gavin P Dunn | |
| Milan G Chheda | |||
| Albert H Kim | |||
| Rowland H Han | |||
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. | Q27853059 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ... | Q27853272 | ||
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial | Q27853299 | ||
| Osimertinib: First Global Approval | Q27853311 | ||
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial | Q27853360 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer | Q57069954 | ||
| Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System | Q57407206 | ||
| Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort | Q57579888 | ||
| The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy | Q58545762 | ||
| Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial | Q58582837 | ||
| Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | Q58607887 | ||
| Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic | Q58609277 | ||
| Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis | Q70211565 | ||
| Brain metastases | Q73257836 | ||
| Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma | Q82849769 | ||
| Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors | Q90981238 | ||
| Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors | Q90981284 | ||
| Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | Q91081830 | ||
| Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | Q91445396 | ||
| TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases | Q92298870 | ||
| Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study | Q52580435 | ||
| Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study | Q52618225 | ||
| Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. | Q52673540 | ||
| Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib | Q52718657 | ||
| The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. | Q54497216 | ||
| Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. | Q54978262 | ||
| Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. | Q54978943 | ||
| ABC4 Consensus: Assessment by a German Group of Experts | Q56968314 | ||
| Targeted Therapies for Brain Metastases from Breast Cancer | Q28068154 | ||
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group | Q28083009 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK | Q29615472 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma | Q30239901 | ||
| Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial | Q33402830 | ||
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial | Q33926135 | ||
| Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases | Q33958338 | ||
| Resistance to BRAF Inhibition in Melanomas | Q34166376 | ||
| ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer | Q34563699 | ||
| Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study | Q34658082 | ||
| Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease | Q34772704 | ||
| Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. | Q35164218 | ||
| (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients | Q35266784 | ||
| Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases | Q35549714 | ||
| Diagnosis and Management of Central Nervous System Metastases from Breast Cancer | Q35552601 | ||
| The biology of brain metastases-translation to new therapies | Q35676602 | ||
| RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors | Q35721081 | ||
| Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. | Q36372466 | ||
| Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? | Q36524188 | ||
| Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases | Q36562180 | ||
| Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma | Q36612452 | ||
| ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. | Q36623819 | ||
| Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer | Q36625206 | ||
| RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors | Q36693087 | ||
| Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events | Q36900721 | ||
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 | ||
| A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320 | Q37087347 | ||
| Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases | Q37274044 | ||
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy | Q37606223 | ||
| Targeted Therapy for Brain Metastases | Q38041723 | ||
| Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer | Q38328139 | ||
| Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer | Q38384492 | ||
| Determinants of outcome in melanoma patients with cerebral metastases | Q38517839 | ||
| The inflammatory microenvironment in brain metastases: potential treatment target? | Q38538141 | ||
| Systemic therapies for melanoma brain metastases: which drug for whom and when? | Q38538148 | ||
| Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). | Q38617638 | ||
| Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy | Q38641116 | ||
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. | Q38645064 | ||
| Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. | Q38737680 | ||
| Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer | Q38761172 | ||
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy | Q38786289 | ||
| Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment | Q38850201 | ||
| Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. | Q39043736 | ||
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. | Q39105350 | ||
| Targeted Treatment of Brain Metastases | Q39192200 | ||
| Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. | Q39354188 | ||
| Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial | Q39365371 | ||
| Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. | Q39586490 | ||
| Activity of T-DM1 in Her2-positive breast cancer brain metastases | Q41455800 | ||
| Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma | Q42706743 | ||
| Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study | Q43522608 | ||
| Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma | Q44276387 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Management of intracranial melanomas in the era of precision medicine | Q44959749 | ||
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer | Q46116627 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis | Q46154570 | ||
| Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement | Q46732334 | ||
| PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. | Q47573421 | ||
| Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial | Q47599265 | ||
| Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer | Q48142933 | ||
| Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. | Q48307824 | ||
| Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation | Q48480145 | ||
| Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. | Q48485643 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| A randomized trial of surgery in the treatment of single metastases to the brain | Q49096659 | ||
| PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review | Q49389686 | ||
| Targeted therapy of brain metastases: latest evidence and clinical implications | Q49956245 | ||
| J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer | Q51003952 | ||
| Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement | Q51069716 | ||
| Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Q52150445 | ||
| P433 | issue | 62 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 6739-6753 | |
| P577 | publication date | 2019-11-19 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | The impact of systemic precision medicine and immunotherapy treatments on brain metastases | |
| P478 | volume | 10 |
| Q94465293 | BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining | cites work | P2860 |
Search more.